Metal and Lipid Nanoparticle Manufacturing Market by Company Size (Very Small Companies, Small Companies, Mid-Sized Companies, and Large Companies), Type of Nanoparticle(s) Manufactured (Lipid and Metal Nanoparticles), Scale of Operation (Preclinical, Clinical, and Commercial), Type of End User (Educational Institutions, Pharmaceutical Companies, Research Institutions, and Other End Users), and Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa (MENA), Latin America, and Rest of the World): Industry Trends and Global Forecasts, 2021-2035

October 2023 | 197 pages | ID: M8E6946D057CEN
Roots Analysis

Abstracts

The projected value of metal and lipid nanoparticle manufacturing market is expected to be valued at USD 2,100 million in 2021 and is anticipated to grow at a CAGR of 8.6% during the forecast period 2021-2035. Over the past few decades, the pharmaceutical industry has witnessed substantial growth, marked by a continuous expansion of the drug development pipeline. However, a comprehensive study published in the Analytical and Pharmaceutical Research journal has shed light on a pressing issue within the industry. It revealed that approximately 90% of drug candidates in the preclinical development phase and over 40% of already marketed pharmacological products exhibit concerns related to solubility and permeability. Furthermore, the study underscored a noteworthy 10% reduction in the efficacy of products resulting from drug incompatibility when combined with other substances.

In response to these challenges, stakeholders in the metal and lipid nanoparticle manufacturing sector are proactively exploring avenues to enhance physiochemical properties and optimize drug behavior. Nanoparticles, particularly lipid nanoparticles, have garnered significant attention for their role in improving drug delivery, a phenomenon notably observed in the development of COVID-19 vaccines. Despite the evident advantages, the industry grapples with complexities in manufacturing processes, necessitating specialized expertise, dedicated infrastructure, and concerns related to stability.

As a pragmatic solution, pharmaceutical companies are increasingly turning to outsourcing for nanoparticle production, relying on specialized service providers. Engaging contract development and manufacturing organizations (CDMOs/CMOs) for the production of medical-grade nanoparticles presents several advantages, including access to cutting-edge technologies, increased production capacities, and operational flexibility. However, despite the claims of various service providers, global expertise in producing Good Manufacturing Practice (GMP)-grade nanoparticles remains limited.

Consequently, many CDMOs/CMOs are strategically aligning themselves through partnerships and alliances to fortify their positions in the metal and lipid nanoparticle manufacturing market. Noteworthy collaborations have emerged, particularly between vaccine developers and CMOs, aimed at addressing the urgent demand for nanoparticle-based solutions in the development of COVID-19 vaccines. Anticipating a sustained need for high-quality nanoparticles, the specialty contract manufacturing market is poised to experience significant growth in the forecast period. This trend is indicative of a broader industry shift toward collaborative efforts to overcome the challenges associated with advanced drug development and nanoparticle utilization.

Research Coverage

• Introduction on nanoparticles, detailing types and applications in the pharmaceutical industry, addressing manufacturing challenges, and discussing the growing trend of outsourcing.
• Detailed nanoparticle contract manufacturing landscape, covering over 50 providers with parameters like establishment year, company size, headquarters location, organization type, nanoparticle types, facilities, operations scale, end users, certifications, regulatory aspects, and services offered.
• Market trends through six schematic representations, depicting company size, headquarters, scale of operation, regional distribution, leading players' analysis, and a grid representation based on various parameters.
• A company competitiveness analysis, evaluating service and partnership strengths across very small, small, mid-sized, and large companies in nanoparticle contract manufacturing.
• Detailed profiles of key players in the market, including company overview, establishment year, headquarters location, employee count, key executives, recent developments, and future outlook.
• Collaborations and partnerships from 2015-2021, categorizing them by agreement type, year, partner type, nanoparticle types, focus areas, seniority levels, active players, and world map representation.
• Insights for nanoparticle-based therapeutics developers, guiding them on the decision to manufacture in-house or engage CMOs, considering parameters relevant to different company sizes.
• A comprehensive market forecast for 2021-2035, predicting growth and distribution across company size, nanoparticle types, scale of operation, end users, and geographical regions.

Key Market Companies

• Ardena
• CordenPharma
• Curia
• Evonik
• LSNE Contract Manufacturing
• Polymun
• TechNanoIndia

Contents

1. PREFACE

1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

3.1. Chapter Overview
3.2. Introduction to Nanoparticles
  3.2.1. Type of Nanoparticles
3.3. Challenges Associated with Manufacturing of Nanoparticles
3.4 Overview of Contract Manufacturing
  3.4.1 Commonly Outsourced Nanoparticle Manufacturing Operations
3.5. Advantages of Outsourcing Nanoparticle Manufacturing Operations
3.6. Key Considerations while Selecting a Contract Manufacturing Partner
3.7. Future Perspective

4. MARKET LANDSCAPE

4.1. Chapter Overview
4.2. Nanoparticle Contract Manufacturers: Overall Market Landscape
  4.2.1. Analysis by Year of Establishment
  4.2.2. Analysis by Company Size
  4.2.3. Analysis by Location of Headquarters
  4.2.4. Analysis by Type of Organization
  4.2.5. Analysis by Type of Nanoparticle(s) Manufactured
  4.2.6. Analysis by Location of Manufacturing Facilities
  4.2.7. Analysis by Scale of Operation
  4.2.8. Analysis by Type of End User
  4.2.9. Analysis by Type of Service(s) Offered
  4.2.10. Analysis by Quality Certifications
  4.2.11. Analysis by Regulatory Organizations
  4.2.12. Leading Nanoparticle Contract Manufacturers: Analysis by Number of Manufacturing Facilities

5. KEY INSIGHTS

5.1. Chapter Overview
5.2. Analysis by Company Size and Type of Organization
5.3. Analysis by Company Size and Type of Nanoparticle(s) Manufactured
5.4. Analysis by Company Size and Scale of Operation
5.5. Analysis by Location of Headquarters (Country-wise)
5.6. Analysis by Company Size, Type of Nanoparticle(s) Manufactured, Number of Manufacturing Facilities, and Number of Services Offered (4D Bubble Representation)
5.7. Analysis by Type of Organization, Type of Nanoparticle(s) Manufactured, Scale of Operation, Type of End User, Type of Service(s) Offered (Grid Representation)

6. COMPANY COMPETITIVENESS ANALYSIS

6.1. Chapter Overview
6.2. Assumptions and Key Parameters
6.3. Methodology
6.4. Benchmarking of Service Strength
6.5. Benchmarking of Partnership Activity
6.6. Nanoparticle Contract Manufacturers: Company Competitiveness Analysis
  6.6.1. Company Competitiveness Analysis: Very Small Companies
  6.6.2. Company Competitiveness Analysis: Small Companies
  6.6.3. Company Competitiveness Analysis: Mid-Sized Companies
  6.6.4. Company Competitiveness Analysis: Large Companies

7. COMPANY PROFILES

7.1. Chapter Overview
7.2. Ardena
  7.2.1. Company Overview
  7.2.2. Recent Developments and Future Outlook
7.3. CordenPharma
  7.3.1. Company Overview
  7.3.2. Recent Developments and Future Outlook
7.4. Curia
  7.4.1. Company Overview
  7.4.2. Recent Developments and Future Outlook
7.5. Evonik
  7.5.1. Company Overview
  7.5.2. Recent Developments and Future Outlook
7.6. LSNE Contract Manufacturing
  7.6.1. Company Overview
  7.6.2. Recent Developments and Future Outlook
7.7. Polymun
  7.7.1. Company Overview
  7.7.2. Recent Developments and Future Outlook
7.8. TechNanoIndia
  7.8.1. Company Overview
  7.8.2. Recent Developments and Future Outlook

8. PARTNERSHIPS AND COLLABORATIONS

8.1. Chapter Overview
8.2. Partnership Models
8.3. Nanoparticle Contract Manufacturing: Partnerships and Collaborations
  8.3.1. Analysis by Year of Partnership
  8.3.2. Analysis by Type of Partnership
  8.3.3. Analysis by Type of Partner
  8.3.4. Analysis by Type of Nanoparticle(s) Manufactured
  8.3.5. Emerging Focus Areas
  8.3.6. Most Active Players: Analysis by Number of Partnerships
  8.3.7. Analysis by Geography
    8.3.7.1. Region-wise Distribution
    8.3.7.2. Country-wise Distribution
8.8. Concluding Remarks

9. OUTSOURCING: GO / NO-GO FRAMEWORK

9.1. Chapter Overview
9.2. Outsourcing: Go / No-Go Framework
9.3. Nanoparticle-based Therapeutics Developers Outsourcing: Go / No-Go Framework
  9.3.1. Assumptions and Parameter Definitions
  9.3.2. Methodology
  9.3.3. Results and Interpretations
    9.3.3.1. Very Small Companies

9. 3.3.2. SMALL COMPANIES

9. 3.3.3. MID-SIZED COMPANIES

9. 3.3.4. LARGE COMPANIES

9. 3.3.4. VERY LARGE COMPANIES

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Nanoparticle Contract Manufacturing Market, 2021-2035
10.4. Nanoparticle Contract Manufacturing Market: Distribution by Company Size, 2021 and 2035
  10.4.1. Nanoparticle Contract Manufacturing Market for Very Small Companies, 2021-2035
  10.4.2. Nanoparticle Contract Manufacturing Market for Small Companies, 2021-2035
  10.4.3. Nanoparticle Contract Manufacturing Market for Mid-Sized Companies, 2021-2035
  10.4.4. Nanoparticle Contract Manufacturing Market for Large Companies, 2021-2035
10.5. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle(s) Manufactured, 2021 and 2035
  10.5.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles, 2021-2035
  10.5.2. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles, 2021-2035
10.6. Nanoparticle Contract Manufacturing Market: Distribution by Scale of Operation, 2021 and 2035
  10.6.1. Nanoparticle Contract Manufacturing Market for Preclinical Scale Operations, 2021-2035
  10.6.2. Nanoparticle Contract Manufacturing Market for Clinical Scale Operations, 2021-2035
  10.6.3. Nanoparticle Contract Manufacturing Market for Commercial Scale Operations, 2021-2035
10.7. Nanoparticle Contract Manufacturing Market: Distribution by Type of End User, 2021 and 2035
  10.7.1. Nanoparticle Contract Manufacturing Market for Educational Institutions, 2021-2035
  10.7.2. Nanoparticle Contract Manufacturing Market for Pharmaceutical Companies, 2021-2035
  10.7.3. Nanoparticle Contract Manufacturing Market for Research Institutions, 2021-2035
  10.7.4. Nanoparticle Contract Manufacturing Market for Other End Users, 2021-2035
10.8. Nanoparticle Contract Manufacturing Market: Distribution by Region, 2021 and 2035
  10.8.1. Nanoparticle Contract Manufacturing Market in North America, 2021-2035
  10.8.2. Nanoparticle Contract Manufacturing Market in Europe, 2021-2035
  10.8.3. Nanoparticle Contract Manufacturing Market in Asia, 2021-2035
  10.8.4. Nanoparticle Contract Manufacturing Market in MENA, 2021-2035
  10.8.5. Nanoparticle Contract Manufacturing Market in Latin America, 2021-2035
  10.8.6. Nanoparticle Contract Manufacturing Market in Rest of the World, 2021-2035
10.9. Nanoparticle Contract Manufacturing Market: Distribution by Type of Nanoparticle and Region, 2021 and 2035
  10.9.1. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in North America, 2021-2035
  10.9.2. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Europe, 2021-2035
  10.9.3. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Asia, 2021-2035
  10.9.4. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in MENA, 2021-2035
  10.9.5. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Latin America, 2021-2035
  10.9.6. Nanoparticle Contract Manufacturing Market for Lipid Nanoparticles in Rest of the World, 2021-2035
  10.9.7. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in North America, 2021-2035
  10.9.8. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Europe, 2021-2035
  10.9.9. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Asia, 2021-2035
  10.9.10. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in MENA, 2021-2035
  10.9.11. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Latin America, 2021-2035
  10.9.12. Nanoparticle Contract Manufacturing Market for Metal Nanoparticles in Rest of the World, 2021-2035
10.10. Concluding Remarks

11. CONCLUDING REMARKS

11.1. Chapter Overview

12. EXECUTIVE INSIGHTS

12.1. Chapter Overview
12.2. LIPOSOMA
  12.2.1. Company Snapshot
  12.2.2. Interview Transcript: Asha Van Rooijen, Founder and Chief Executive Officer, Bart Metselaar, Director, Research and Development

13. APPENDIX I: TABULATED DATA

14. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION